CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Intrinsic Value
CSPC Innovation Pharmaceutical Co., Ltd. manufactures and sells active pharmaceutical ingredient, including caffeine, theophylline, aminophylline, diprophylline, theobromine, pentoxifylline, doxofylli... [ Read More ]
The intrinsic value of one CSPC Innovation Pharmaceutical Co Ltd stock under the Base Case scenario is 23.45 CNY. Compared to the current market price of 33.3 CNY, CSPC Innovation Pharmaceutical Co Ltd is Overvalued by 30%.
Valuation Backtest
CSPC Innovation Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling CSPC Innovation Pharmaceutical Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
CSPC Innovation Pharmaceutical Co Ltd
| Current Assets | 4.2B |
| Cash & Short-Term Investments | 3.4B |
| Receivables | 553m |
| Other Current Assets | 244.7m |
| Non-Current Assets | 1.4B |
| Long-Term Investments | 267.1m |
| PP&E | 1.1B |
| Intangibles | 48m |
| Other Non-Current Assets | 17.4m |
| Current Liabilities | 510.8m |
| Accounts Payable | 173.7m |
| Accrued Liabilities | 60.8m |
| Short-Term Debt | 9.7m |
| Other Current Liabilities | 266.6m |
| Non-Current Liabilities | 42.5m |
| Long-Term Debt | 841.2k |
| Other Non-Current Liabilities | 41.6m |
Earnings Waterfall
CSPC Innovation Pharmaceutical Co Ltd
|
Revenue
|
2.5B
CNY
|
|
Cost of Revenue
|
-1.4B
CNY
|
|
Gross Profit
|
1.1B
CNY
|
|
Operating Expenses
|
-346.3m
CNY
|
|
Operating Income
|
787.7m
CNY
|
|
Other Expenses
|
-32.1m
CNY
|
|
Net Income
|
755.6m
CNY
|
Free Cash Flow Analysis
CSPC Innovation Pharmaceutical Co Ltd
Profitability Score
Profitability Due Diligence
CSPC Innovation Pharmaceutical Co Ltd's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
Score
CSPC Innovation Pharmaceutical Co Ltd's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
CSPC Innovation Pharmaceutical Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
CSPC Innovation Pharmaceutical Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
CSPC Innovation Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for CSPC Innovation Pharmaceutical Co Ltd is 50.31 CNY with a low forecast of 46.61 CNY and a high forecast of 55.13 CNY.
Shareholder Return
Price
CSPC Innovation Pharmaceutical Co Ltd
| Average Annual Return | 2.16% |
| Standard Deviation of Annual Returns | 12.38% |
| Max Drawdown | -99% |
| Market Capitalization | 39B CNY |
| Shares Outstanding | 1 170 742 154 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
CSPC Innovation Pharmaceutical Co., Ltd. manufactures and sells active pharmaceutical ingredient, including caffeine, theophylline, aminophylline, diprophylline, theobromine, pentoxifylline, doxofylline, psychotropic drugs (caffeine) and food additives (caffeine). The company is headquartered in Shijiazhuang, Hebei and currently employs 1,524 full-time employees. The company went IPO on 2019-03-22. The firm's main products include caffeine products, vitamin products and other functional foods. The Company’s caffeine products are mainly caffeine, including a small amount of theophylline, aminophylline and theobromine. The vitamin products are mainly vitamin C tablets, including a small amount of vitamin C drinks. The firm mainly distributes its products both in the domestic market and to overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one CSPC Innovation Pharmaceutical Co Ltd stock under the Base Case scenario is 23.45 CNY.
Compared to the current market price of 33.3 CNY, CSPC Innovation Pharmaceutical Co Ltd is Overvalued by 30%.
You don't have any saved screeners yet
